

CADTH RAPID RESPONSE REPORT: REFERENCE LIST

Enzyme Replacement Therapy and Eliglustat for Gaucher Disease Type 1: Guidelines

Service Line: Rapid Response Service
Version: 1.0
Publication Date: September 20, 2019
Report Length: 5 Pages

Authors: Christopher Freige, Carolyn Spry

Cite As: *Enzyme Replacement Therapy and Eliglustat for Gaucher Disease Type 1: Guidelines*. Ottawa: CADTH; 2019 Sept. (CADTH rapid response report: reference list).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Research Question

What are the evidence-based guidelines for prescribing enzyme replacement therapies (ERT) and eliglustat in Gaucher disease Type 1?

Key Findings

No evidence-based guidelines were identified regarding prescribing ERT and eliglustat in Gaucher disease Type 1.

Methods

A limited literature search was conducted by an information specialist on key resources including Medline, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were Gaucher Disease and enzyme replacement therapy or eliglustat. No filters were applied to limit retrieval by publication type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and September 16, 2019. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Patients of all ages with Gaucher disease Type 1
Interventions	Enzyme replacement therapies (ERT): imiglucerase, taliglucerase, velaglucerase Eliglustat
Comparator	Not applicable
Outcomes	Guidelines
Study Designs	Evidence-based guidelines

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Normally, health technology assessment reports, systematic reviews, and meta-analyses are presented first; however, in reports where guidelines are primarily sought, the aforementioned evidence types are presented in the appendix.

No evidence-based guidelines were identified regarding prescribing ERT therapies and eliglustat in Gaucher disease Type 1.

References of potential interest are provided in the appendix.

Guidelines and Recommendations

No literature identified.

Appendix — Further Information

Previous CADTH Reports

1. Enzyme replacement therapy for the treatment of Gaucher disease type 1: clinical effectiveness. (*CADTH Rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2017: <https://www.cadth.ca/enzyme-replacement-therapy-treatment-gaucher-disease-type-1-clinical-effectiveness-0>. Accessed 2019 Sep 19.
2. Eliglustat (Cerdelga). (Sanofi Genzyme). Indication: Gaucher disease type 1. (*CADTH Common Drug Review*). Ottawa (ON): CADTH; 2016: <https://www.cadth.ca/eliglustat>. Accessed 2019 Sep 19.
3. Taliglucerase alfa (Elelyso). (Pfizer Canada Inc.). Indication: Gaucher disease. (*CADTH Common Drug Review*). Ottawa (ON): CADTH; 2014: <https://www.cadth.ca/taliglucerase-alfa-4>. Accessed 2019 Sep 19.

Health Technology Assessments

4. All Wales Medicines Strategy Group (AWMSG). Velaglucerase alfa. (*AWMSG Secretariat Assessment Report Advice No. 1214*). Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG); 2014: <http://www.awmsg.org/awmsgonline/app/appraisalinfo/571>. Accessed 2019 Sep 19.

Systematic Reviews and Meta-analyses

5. Nabizadeh A, Amani B, Kadivar M, et al. The clinical efficacy of imiglucerase versus eliglustat in patients with Gaucher's disease type 1: a systematic review. *J Res Pharm Pract*. 2018 Oct-Dec;7(4):171-177. [PubMed: PM30622983](#)
6. Shemesh E, Deroma L, Bembi B, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. *Cochrane Database Syst Rev*. 2015 Mar 27(3):CD010324. [PubMed: PM25812601](#)
7. Smid BE, Hollak CE. A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease. *Expert Opin Orphan Drugs*. 2014; 2(5): 523-529.

Clinical Practice Guidelines and Recommendations

Unclear Methodology

8. Puri RD, Kapoor S, Kishnani PS, et al. Diagnosis and management of Gaucher disease in India - consensus guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. *Indian Pediatr*. 2018 02 15;55(2):143-153. [PubMed: PM29503270](#)

9. Belmatoug N, Di Rocco M, Fraga C, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. *Eur J Intern Med.* 2017 Jan;37:25-32.
[PubMed: PM27522145](#)
10. Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. *Mol Genet Metab.* 2016 Feb;117(2):95-103.
[PubMed: PM26387627](#)

Review Articles

11. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. *Expert Rev Endocrinol Metab.* 2018 03;13(2):107-118.
[PubMed: PM30058864](#)
12. Gupta P, Pastores G. Pharmacological treatment of pediatric Gaucher disease. *Expert Rev Clin Pharmacol.* 2018 Dec;11(12):1183-1194.
[PubMed: PM30444430](#)
13. Rosenbaum H. Management of women with Gaucher disease in the reproductive age. *Thromb Res.* 2015 Feb;135 Suppl 1:S49-51.
[PubMed: PM25903536](#)